The objective of this study was to examine the effects of nattokinase supplementation on blood pressure in subjects with pre-hypertension or stage 1 hypertension. In a randomized, double-blind, placebo-controlled trial, 86 participants ranging from 20 to 80 years of age with an initial untreated systolic blood pressure (SBP) of 130 to 159 mmHg received nattokinase (2,000 FU/capsule) or a placebo capsule for 8 weeks. Seventy-three subjects completed the protocol. Compared with the control group, the net changes in SBP and diastolic blood pressure (DBP) were −5.55 mmHg (95% confidence interval [CI], −10.5 to −0.57 mmHg; p <0.05) and −2.84 mmHg (CI, −5.33 to −0.33 mmHg; p >0.05), respectively, after the 8-week intervention. The corresponding net change in renin activity was −1.17 ng/mL/h for the nattokinase group compared with the control group (p <0.05). In conclusion, nattokinase supplementation resulted in a reduction in SBP and DBP. These findings suggest that increased intake of nattokinase may play an important role in preventing and treating hypertension.
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J : Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365 ( 9455): 217–223.
Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572.
Gu D, Reynolds K, Wu X, et al, InterASIA Collaborative Group: The International Collaborative Study of Cardiovascular Disease in ASIA. Prevalence, awareness, treatment, and control of hypertension in china. Hypertension 2002; 40: 920–927.
Choi KM, Park HS, Han JH, et al: Prevalence of prehypertension and hypertension in a Korean population: Korean National Health and Nutrition Survey 2001. J Hypertens 2006; 24: 1515–1521.
Whelton PK, He J, Appel LJ, et al; National High Blood Pressure Education Program Coordinating Committee: Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA 2002; 288: 1882–1888.
Neaton JD, Grimm RH Jr, Prineas RJ, et al: Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993; 270: 713–724.
Iseki K, Kimura Y, Wakugami K, et al: Comparison of the effect of blood pressure on the development of stroke, acute myocardial infarction, and end-stage renal disease. Hypertens Res 2000; 23: 143–149.
Artaud-Wild SM, Connor SL, Sexton G, Connor WE : Differences in coronary mortality can be explained by differences in cholesterol and saturated fat intakes in 40 countries but not in France and Finland. A paradox. Circulation 1993; 88: 2771–2779.
Keys A, Menotti A, Aravanis C, et al: The seven countries study: 2,289 deaths in 15 years. Prev Med 1984; 13: 141.
Golbitz P : Traditional soy foods: processing and products. J Nutr 1995; 125 ( 3 Suppl): 570S–572S.
Fujita M, Ito Y, Hong K, Nishimuro S : Characterization of Nattokinase-degraded products from human fibrinogen or cross-linked fibrin. Fibrinolysis 1995; 9: 157.
Fujita M, Nomura K, Hong K, Ito Y, Asada A, Nishimuro S : Purification and characterization of a strong fibrinolytic enzyme (nattokinase) in the vegetable cheese natto, a popular soybean fermented food in Japan. Biochem Biophys Res Commun 1993; 197: 1340–1347.
Urano T, Ihara H, Umemura K, et al: The profibrinolytic enzyme subtilisin NAT purified from Bacillus subtilis Cleaves and inactivates plasminogen activator inhibitor type 1. J Biol Chem 2001; 276: 24690–24696.
Jalil JE, Piddo AM, Cordova S, et al: Prevalence of the angiotensin I converting enzyme insertion/deletion polymorphism, plasma angiotensin converting enzyme activity, and left ventricular mass in a normotensive Chilean population. Am J Hypertens 1999; 12: 697–704.
Christian JL, Greger JH : Nutrition for Living. San Francisco, The Benjamin/Cummings Publ Comp Inc, 1991, p 111.
American Dietetic Association: Handbook of Clinical Dietetics, 2nd ed, New Haven, Yale University Press, 1992, pp 5–39.
Suzuki Y, Kondo K, Ichise H, Tsukamoto Y, Urano T, Umemura K : Dietary supplementation with fermented soybeans suppresses intimal thickening. Nutrition 2003; 19: 261–264.
Suzuki Y, Kondo K, Matsumoto Y, et al: Dietary supplementation of fermented soybean, natto, suppresses intimal thickening and modulates the lysis of mural thrombi after endothelial injury in rat femoral artery. Life Sci 2003; 73: 1289–1298.
Fujita M, Hong K, Ito Y, Fujii R, Kariya K, Nishimuro S : Thrombolytic effect of nattokinase on a chemically induced thrombosis model in rat. Biol Pharm Bull 1995; 18: 1387–1391.
Pais E, Alexy T, Holsworth RE Jr, Meiselman HJ : Effects of nattokinase, a pro-fibrinolytic enzyme, on red blood cell aggregation and whole blood viscosity. Clin Hemorheol Microcirc 2006; 35: 139–142.
Maruyama M, Sumi H ( eds): Effect of natto diet on blood pressure, in Basic and Clinical Aspects of Japanese Traditional Food Natto II. Japan Technology Transfer Association (JTTAS), 1998, pp 1–3.
Kim S, Yamamoto K : The in vivo role of renin-angiotensin system. Cell Science 1992; 8: 146–151.
Okamoto A, Hanagata H, Kawamura Y, Yanagida F : Antihypertensive substances in fermented soybean, natto. Plant Foods Hum Nutr 1995; 47: 39–47.
Kuba M, Tanaka K, Tawata S, Takeda Y, Yasuda M : Angiotensin I—converting enzyme inhibitory peptides isolated from tofuyo fermented soybean food. Biosci Biotechnol Biochem 2003; 67: 1278–1283.
About this article
Cite this article
Kim, J., Gum, S., Paik, J. et al. Effects of Nattokinase on Blood Pressure: A Randomized, Controlled Trial. Hypertens Res 31, 1583–1588 (2008). https://doi.org/10.1291/hypres.31.1583
- blood pressure
- renin activity
- controlled trial
Acute toxicity and genotoxicity evaluations of Nattokinase, a promising agent for cardiovascular diseases prevention
Regulatory Toxicology and Pharmacology (2019)
Study on molecular mechanisms of nattokinase in pharmacological action based on label‐free liquid chromatography–tandem mass spectrometry
Food Science & Nutrition (2019)
Comparative anti-thrombotic activity and haemorrhagic adverse effect of nattokinase and tissue-type plasminogen activator
Food Science and Biotechnology (2019)
Biomarker Insights (2018)
Scientific Reports (2015)